TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03474224

Intervention type: DEVICE
Intervention: Ev1000 Clinical Platform from Edwards Lifesciences
Description: The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
Study: NCT01126892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT01206465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study: NCT03667430

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porous silica
Description: The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porous silica
Description: The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (microcrystalline cellulose)
Description: All participants starts with five days placebo run in period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (microcrystalline cellulose)
Description: All participants starts with five days placebo run in period
Study: NCT01392599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)
Description: After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
Study: NCT01174576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeinated and decaffeinated coffee
Description: 3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
Study: NCT01891214

Intervention type: OTHER
Intervention: Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)
Study: NCT05567536

Intervention type: DRUG
Intervention: Antiplatelet Agents
Description: Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent

Intervention type: DRUG
Intervention: Antiplatelet Agents
Description: Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent
Study: NCT02265289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefradafiban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study: NCT02392520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetrorelix (cetrotide)
Description: 0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
Study: NCT00678613

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics and Placebo
Description: The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics and Norfloxacin
Description: The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
Study: NCT03955562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Footbridge
Description: Access to a pedestrian footbridge.
Study: NCT03059914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterOss
Description: Anorganic bovine bone mineral - Xenograft

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-oss
Description: Anorganic bovine bone mineral ( Xenograft)
Study: NCT02461693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200mg delivered as pill; one-time dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose-based pill; one-time dose
Study: NCT03468842

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Already described

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00383799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv Amiodarone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv Procainamide
Study: NCT01300403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flutter valve
Description: Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expiration with the glottis open in lateral posture (ELTGOL)
Description: This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
Study: NCT00787826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Francisella Tularensis Vaccine
Description: Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20.
Study: NCT00583648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urinanlysis
Description: sending a Urine sample to the laboratory for processing
Study: NCT03894358

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeFum and 7.5 g prebiotic mixture
Description: The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture~The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:~Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.~Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeFum and 3 g prebiotic mixture
Description: Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fefum and no prebiotic mixture
Description: Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
Study: NCT04752930

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA monitoring
Description: Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled, and diagnostic laparoscopy will be performed immediately after enrollment. Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months in patients with negative peritoneal metastasis. Laparoscopy will be performed when imaging suggested peritoneal metastasis (oligometastases). Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Imageology
Description: Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled. and there will be no need to conduct endoscopic exploration immediately after enrollment. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months until imaging suggested peritoneal metastasis (oligometastases). Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
Study: NCT00626288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: Mesalazine 800mg t.i.d. 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cpr, t.i.d. 12 weeks
Study: NCT02024061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular treatment
Description: The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
Study: NCT03385733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: The treatment group received IMT. Patients were trained using an inspiratory threshold-loading device
Study: NCT01099046

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: water intake, tympanic tubing, regular sleep

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: water intake, tympanic tubing, regular sleep

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: water intake, tympanic tubing, regular sleep

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Lifestyle
Description: water intake, tympanic tubing, regular sleep
Study: NCT00873158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen
Study: NCT03037840

Intervention type: DEVICE
Intervention: Low intensity amplitude-modulated RF EMFs
Description: Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW

Intervention type: DEVICE
Intervention: Low intensity amplitude-modulated RF EMFs
Description: Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
Study: NCT04042831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT01100385

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ateronon
Description: Tomato extract (lycopene) capsule, taken once daily for 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ateronon
Description: Tomato extract (lycopene) capsule, taken once daily for 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsule, taken once daily for 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsule, taken once daily for 56 days
Study: NCT03733808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation technique

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation technique
Study: NCT01005238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Study: NCT00494663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 150mg tablet once per day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 300mg tablet once per day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 450mg DIO-902 tablet once daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DIO-902 placebo
Description: DIO-902 placebo tablet once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 150mg tablet of DIO-902 once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 300mg DIO-902 tablet daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 450mg DIO-902 tablet for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DIO-902 placebo
Description: DIO-902 placebo tablet once daily for 16 weeks
Study: NCT02198196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Talk-Mindfulness
Study: NCT02532036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosol inhaled MVA85A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosol inhaled MVA85A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular MVA85A
Study: NCT03955562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison villages
Description: Villages that do not receive a footbridge.
Study: NCT02532036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosol inhaled Saline placebo
Study: NCT02732639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (PEG-IFN) alfa-2a
Description: Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
Study: NCT01618253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional fractionation (2 Gy per day) external beam radiation therapy
Description: Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or \>10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If \>1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.~The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions \>10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced.
Study: NCT02075476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reverse arthroplasty
Study: NCT06042322

Intervention type: OTHER
Intervention: Educational intervention
Description: Multidisciplinary educational intervention was performed by orthopedic, anesthesia, and nursing team. This included a discussion of the patient's pain plan and a patient visit.
Study: NCT04630041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 211 Referral
Description: Patients with one or more reported social need will be referred to 211 for community based services. 211 will reach out and contact patients for follow-up.
Study: NCT02116790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Subjects will take one 250mg Naproxen capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Subjects will take one 250mg Naproxen capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Subjects will take one 250mg Naproxen capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet
Description: Subjects will take one 12.5mg/50mg Sinemet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet
Description: Subjects will take one 25mg/100mg Sinemet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take two placebos.
Study: NCT01195948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B27PD
Study: NCT02860936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
Study: NCT01670864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling group
Description: The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week \& 1-month will be made to the participants in this group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS intervention group
Description: The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
Study: NCT03377465

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin
Description: ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin
Description: ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
Study: NCT03540862

Intervention type: DEVICE
Intervention: maintenance negative pressure ventilation (Philips Respironics Lifecare NEV-100)
Description: hospital-based NPV once every week as the maintenance program
Study: NCT02415530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined home visiting and group intervention
Description: home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3\~6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT01959100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 250 mg x 3/week per os during a meal for a period of 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mg x 3/week during a meal for a period of 2 years